BMY vs MDXG: fair value comparison
Bristol-Myers Squibb Company and MiMedx Group, Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our discount ranking. BMY carries the stronger quality grade.
| BMY | MDXG | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $63.64 | $4.52 |
| 12-month range | $46.02–$66.92 | $3.58–$7.52 |
| Sector rank | #99 of 113 Healthcare | #100 of 113 Healthcare |
| Quality grade | B | D |
| Leverage | High | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: BMY fair value analysis · MDXG fair value analysis